APO Research
Talk to an analyst

APO RESEARCH · REPORT

Dipeptidyl Peptidase IV (DPP-IV) Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025180 pages

Choose your research edition.

Industry ResearchDipeptidyl Peptidase IV (DPP-IV) Inhibitors Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Dipeptidyl Peptidase IV (DPP-IV) Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Dipeptidyl Peptidase IV (DPP-IV) Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Dipeptidyl Peptidase IV (DPP-IV) Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Dipeptidyl Peptidase IV (DPP-IV) Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Dipeptidyl Peptidase IV (DPP-IV) Inhibitors include Takeda, Novartis, Merck, Eli Lilly, AstraZeneca, Mitsubishi Tanabe Pharma and Boehringer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Dipeptidyl Peptidase IV (DPP-IV) Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Dipeptidyl Peptidase IV (DPP-IV) Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Dipeptidyl Peptidase IV (DPP-IV) Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Segment by Company

Takeda

Novartis

Merck

Eli Lilly

AstraZeneca

Mitsubishi Tanabe Pharma

Boehringer

Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Segment by Type

Vildagliptin

Saxagliptin

Sitagliptin

Linagliptin

Others

Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Dipeptidyl Peptidase IV (DPP-IV) Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dipeptidyl Peptidase IV (DPP-IV) Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Dipeptidyl Peptidase IV (DPP-IV) Inhibitors market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Dipeptidyl Peptidase IV (DPP-IV) Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Dipeptidyl Peptidase IV (DPP-IV) Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Dipeptidyl Peptidase IV (DPP-IV) Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Industry Trends Table 2. Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Industry Drivers Table 3. Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Industry Opportunities and Challenges Table 4. Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Industry Restraints Table 5. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Manufacturers (k tons) & (2021-2026) Table 8. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Market Share by Manufacturers Table 9. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Average Sales Price (US$/ton) of Manufacturers (2021-2026) Table 10. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Manufacturers, Product Type & Application Table 13. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Vildagliptin Table 17. Major Manufacturers of Saxagliptin Table 18. Major Manufacturers of Sitagliptin Table 19. Major Manufacturers of Linagliptin Table 20. Major Manufacturers of Others Table 21. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Type 2021 VS 2025 VS 2032 (k tons) Table 22. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Type (2021-2026) & (k tons) Table 23. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Type (2027-2032) & (k tons) Table 24. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Market Share by Type (2021-2026) Table 25. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Market Share by Type (2027-2032) Table 26. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (k tons) Table 27. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue by Type (2021-2026) & (k tons) Table 28. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue by Type (2027-2032) & (k tons) Table 29. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue Market Share by Type (2021-2026) Table 30. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Hospital Pharmacies Table 32. Major Manufacturers of Online Pharmacies Table 33. Major Manufacturers of Retail Pharmacies Table 34. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Application 2021 VS 2025 VS 2032 (k tons) Table 35. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Application (2021-2026) & (k tons) Table 36. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Application (2027-2032) & (k tons) Table 37. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Market Share by Application (2021-2026) Table 38. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Market Share by Application (2027-2032) Table 39. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (k tons) Table 40. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue by Application (2021-2026) & (k tons) Table 41. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue by Application (2027-2032) & (k tons) Table 42. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue Market Share by Application (2021-2026) Table 43. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue Market Share by Application (2027-2032) Table 44. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (k tons) Table 45. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Region (2021-2026) & (k tons) Table 46. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Market Share by Region (2021-2026) Table 47. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Forecasted by Region (2027-2032) & (k tons) Table 48. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 50. North America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Country (2021-2026) & (k tons) Table 51. North America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Country (2027-2032) & (k tons) Table 52. Europe Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 53. Europe Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Country (2021-2026) & (k tons) Table 54. Europe Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Country (2027-2032) & (k tons) Table 55. Asia Pacific Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 56. Asia Pacific Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Country (2021-2026) & (k tons) Table 57. Asia Pacific Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Country (2027-2032) & (k tons) Table 58. South America, Middle East and Africa Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 59. South America, Middle East and Africa Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Country (2021-2026) & (k tons) Table 60. South America, Middle East and Africa Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Country (2027-2032) & (k tons) Table 61. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue Market Share by Region (2021-2026) Table 65. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue Market Share by Region (2027-2032) Table 66. Takeda Company Information Table 67. Takeda Business Overview Table 68. Takeda Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Takeda Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Product Portfolio Table 70. Takeda Recent Development Table 71. Novartis Company Information Table 72. Novartis Business Overview Table 73. Novartis Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Novartis Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Product Portfolio Table 75. Novartis Recent Development Table 76. Merck Company Information Table 77. Merck Business Overview Table 78. Merck Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Merck Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Product Portfolio Table 80. Merck Recent Development Table 81. Eli Lilly Company Information Table 82. Eli Lilly Business Overview Table 83. Eli Lilly Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Eli Lilly Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Product Portfolio Table 85. Eli Lilly Recent Development Table 86. AstraZeneca Company Information Table 87. AstraZeneca Business Overview Table 88. AstraZeneca Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. AstraZeneca Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Product Portfolio Table 90. AstraZeneca Recent Development Table 91. Mitsubishi Tanabe Pharma Company Information Table 92. Mitsubishi Tanabe Pharma Business Overview Table 93. Mitsubishi Tanabe Pharma Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Mitsubishi Tanabe Pharma Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Product Portfolio Table 95. Mitsubishi Tanabe Pharma Recent Development Table 96. Boehringer Company Information Table 97. Boehringer Business Overview Table 98. Boehringer Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Boehringer Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Product Portfolio Table 100. Boehringer Recent Development Table 101. Key Raw Materials Table 102. Raw Materials Key Suppliers Table 103. Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Distributors List Table 104. Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Customers List Table 105. Research Programs/Design for This Report Table 106. Authors List of This Report Table 107. Secondary Sources Table 108. Primary Sources List of Figures Figure 1. Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Product Image Figure 2. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales (2021-2032) & (k tons) Figure 5. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Average Price (US$/ton) & (2021-2032) Figure 6. Global Top 5 and 10 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Vildagliptin Image Figure 9. Saxagliptin Image Figure 10. Sitagliptin Image Figure 11. Linagliptin Image Figure 12. Others Image Figure 13. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (k tons) Figure 14. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Market Share by Type (2021-2032) Figure 16. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (k tons) Figure 17. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue Market Share by Type (2021-2032) Figure 19. Hospital Pharmacies Image Figure 20. Online Pharmacies Image Figure 21. Retail Pharmacies Image Figure 22. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (k tons) Figure 23. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Market Share by Application (2021-2032) Figure 25. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (k tons) Figure 26. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue Market Share by Application (2021-2032) Figure 28. North America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 29. North America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Market Share by Country (2021-2032) Figure 30. U.S. Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 31. Canada Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 32. Mexico Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 33. Europe Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 34. Europe Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Market Share by Country (2021-2032) Figure 35. Germany Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 36. France Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 37. U.K. Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 38. Italy Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 39. Netherlands Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 40. Asia Pacific Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 41. Asia Pacific Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Market Share by Country (2021-2032) Figure 42. China Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 43. Japan Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 44. South Korea Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 45. Southeast Asia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 46. India Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 47. Australia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 48. South America, Middle East and Africa Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 49. South America, Middle East and Africa Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Market Share by Country (2021-2032) Figure 50. Brazil Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 51. South Africa Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 52. Saudi Arabia Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 53. Turkey Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 54. Argentina Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 55. UAE Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 56. Egypt Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 57. Chile Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales and Growth Rate (2021-2032) & (k tons) Figure 58. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue (2021-2032) & (US$ Million) Figure 61. North America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue (2021-2032) & (US$ Million) Figure 63. Europe Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Vildagliptin
  • Saxagliptin
  • Sitagliptin
  • Linagliptin
  • Others
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Takeda
  • Novartis
  • Merck
  • Eli Lilly
  • AstraZeneca
  • Mitsubishi Tanabe Pharma
  • Boehringer

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Dynamics
  1. 2.1 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Industry Trends
  2. 2.2 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Industry Drivers
  3. 2.3 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Industry Opportunities and Challenges
  4. 2.4 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Industry Restraints
3 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market by Manufacturers
  1. 3.1 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Manufacturers (2021-2026)
  3. 3.3 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Manufacturers, Product Type & Application
  7. 3.7 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Tier 1, Tier 2, and Tier 3
4 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market by Type
  1. 4.1 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Type Introduction
  2. 4.1.1 Vildagliptin
  3. 4.1.2 Saxagliptin
  4. 4.1.3 Sitagliptin
  5. 4.1.4 Linagliptin
  6. 4.1.5 Others
  7. 4.2 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Type
  8. 4.2.1 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Type (2021-2032)
  10. 4.2.3 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Market Share by Type (2021-2032)
  11. 4.3 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue by Type
  12. 4.3.1 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue by Type (2021-2032)
  14. 4.3.3 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue Market Share by Type (2021-2032)
5 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market by Application
  1. 5.1 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Application
  6. 5.2.1 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Application (2021-2032)
  8. 5.2.3 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Market Share by Application (2021-2032)
  9. 5.3 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue by Application
  10. 5.3.1 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue by Application (2021-2032)
  12. 5.3.3 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue Market Share by Application (2021-2032)
6 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Region
  1. 6.1 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Region (2021-2026)
  4. 6.2.2 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue by Region
  1. 7.1 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue by Region
  2. 7.1.1 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue by Region (2021-2026)
  4. 7.1.3 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue by Region (2027-2032)
  5. 7.1.4 Global Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue (2021-2032)
  8. 7.2.2 North America Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue (2021-2032)
  11. 7.3.2 Europe Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 Eli Lilly
  20. 8.4.1 Eli Lilly Company Information
  21. 8.4.2 Eli Lilly Business Overview
  22. 8.4.3 Eli Lilly Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Eli Lilly Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Product Portfolio
  24. 8.4.5 Eli Lilly Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 Mitsubishi Tanabe Pharma
  32. 8.6.1 Mitsubishi Tanabe Pharma Company Information
  33. 8.6.2 Mitsubishi Tanabe Pharma Business Overview
  34. 8.6.3 Mitsubishi Tanabe Pharma Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Mitsubishi Tanabe Pharma Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Product Portfolio
  36. 8.6.5 Mitsubishi Tanabe Pharma Recent Developments
  37. 8.7 Boehringer
  38. 8.7.1 Boehringer Company Information
  39. 8.7.2 Boehringer Business Overview
  40. 8.7.3 Boehringer Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Boehringer Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Product Portfolio
  42. 8.7.5 Boehringer Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Value Chain Analysis
  2. 9.1.1 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Production Mode & Process
  6. 9.2 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Distributors
  9. 9.2.3 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst